Radiotherapy clinical trials at UCSF
1 research study open to eligible people
Radiotherapy uses high-energy rays to treat cancer. UCSF is recruiting for trials using radiotherapy to activate a drug called NBTXR3 in patients with advanced cancers. These trials also involve treatments with anti-PD-1 therapy.
Showing trials for
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
open to eligible people ages 18 years and up
The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.
San Francisco, California and other locations
Last updated: